Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 79 of the 81 references it cites were found in a registry or an index, and 2 are not checked yet; 80 of the 107 sources its claims cite were checked for support.

Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies

Open access
Kano, Yoshihito · 2026 · International Journal of Molecular Sciences

Abstract

KRAS is one of the most frequently mutated oncogenes in human cancer and has long been considered an “undruggable” therapeutic target because of its high affinity for guanine nucleotides and limited druggable binding pockets. Recent advances in structural biology and molecular pharmacology have transformed this paradigm, leading to the successful development of KRAS G12C inhibitors such as sotorasib and adagrasib. These agents established proof-of-concept for direct KRAS inhibition and marked an important advance in precision oncology. However, intrinsic and acquired resistance mechanisms, adaptive signaling reactivation, and tumor heterogeneity continue to limit the durability of clinical responses. Therapeutic development has rapidly expanded beyond KRAS G12C toward broader strategies including KRAS G12D inhibitors, pan-RAS and RAS(ON) inhibitors, degraders, and biomarker-guided combination approaches. In parallel, circulating tumor DNA (ctDNA) and other biomarker-driven strategies are increasingly enabling dynamic monitoring of treatment response, minimal residual disease, and resistance evolution. In this review, we summarize the molecular biology and conformational regulation of KRAS signaling, recent advances in allele-specific and pan-RAS therapeutic strategies, mechanisms of resistance, and emerging precision oncology frameworks for KRAS-mutant cancers.

Verified 2026-10-10 · 2 references not checked yet

Overview

CoChat Summary

TL;DR

This narrative review synthesizes the shift in KRAS-targeted oncology from G12C OFF-state inhibitors toward G12D, RAS(ON)/pan-RAS, degrader, and biomarker-guided strategies. It argues that KRAS allele, nucleotide/conformational state, tumor lineage, resistance mechanism, and ctDNA dynamics should guide therapy, while noting many non-G12C and pan-RAS approaches remain investigational.

Key findings

  • KRAS G12C inhibitors established proof-of-concept but show lineage-dependent efficacy: in CodeBreaK 100, sotorasib produced an ORR of approximately 41%, median PFS of 6.3 months, and median OS of 12.5 months; in CodeBreaK 200, sotorasib improved PFS versus docetaxel (5.6 vs. 4.5 months; HR 0.66) and ORR (28.1% vs. 13.2%), but not OS (10.6 vs. 11.3 months; HR 1.01).
  • EGFR blockade is needed in KRAS G12C-mutant colorectal cancer because of rapid EGFR-mediated adaptive reactivation: KRYSTAL-1 reported adagrasib plus cetuximab ORR 34.0%, median PFS 6.9 months, and median OS 15.9 months; CodeBreaK 300 reported sotorasib plus panitumumab median PFS 5.6 vs. 2.2 months and ORR 26% vs. 0%.
  • Beyond G12C, KRAS G12D lacks a covalent cysteine handle and requires non-covalent or active-state strategies; MRTX1133 provided preclinical proof-of-concept but its clinical trial was terminated for formulation challenges, while zoldonrasib and other G12D agents remain in early evaluation.
  • RAS(ON)/pan-RAS inhibition may broaden allele coverage: in the phase III RASolute 302 trial in previously treated metastatic PDAC, daraxonrasib improved median OS (13.2 vs. 6.7 months) and median PFS (7.2 vs. 3.6 months) versus chemotherapy, though wild-type RAS inhibition and therapeutic window remain concerns.

Methods

  • Narrative review with a scoping approach, not a systematic review or meta-analysis; literature was identified from PubMed, ClinicalTrials.gov, regulatory documents, major oncology conference abstracts, and publicly available company disclosures up to May 2026.
  • Evidence was categorized by maturity: Level 1, approved therapy or randomized phase III; Level 2, peer-reviewed phase I/II; Level 3, registry data, conference abstracts, or company disclosures without mature peer-reviewed publication; Level 4, preclinical; Level 5, conceptual or hypothesis-generating.
  • Priority was given to peer-reviewed original studies, randomized clinical trials, regulatory documents, and clinical trial registry records; conference abstracts and company disclosures were included only when peer-reviewed data were unavailable and are indicated as preliminary or non-peer-reviewed.

Limitations

  • Stated: the article is a narrative review with a scoping approach and was not designed as a systematic review or meta-analysis; conclusions were calibrated according to an evidence hierarchy, and non-peer-reviewed sources are flagged when used.
  • Stated: biomarker-guided treatment utility remains uneven—KRAS allele status is clinically actionable, but ctDNA-guided treatment switching, MRD-based escalation, and perioperative adaptation remain investigational; co-mutations, tumor lineage, and serial ctDNA dynamics are variably validated.
  • Evident: the review relies on secondary literature and rapidly evolving clinical data, and many discussed agents are preclinical, early-stage, or discontinued (e.g., MRTX1133, JDQ443), limiting the durability and generalizability of conclusions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms27135796

Cites

79 of 81 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Mechanistic classes of KRAS-targeted therapies. The Upper panels compare key mechanistic features and illustrate the canonical KRAS GDP/GTP activation cycle. The Lower Panels: KRAS-targeted strategies have evolved from allele-specific KRAS G12C inhibition to KRAS G12D inhibition, multi-selective RAS targeting/RAS(ON) active-state inhibition, and targeted protein degradation. KRAS G12C inhibitors covalently bind the switch-II pocket of GDP-bound KRAS G12C and trap KRAS in an inactive OFF state, whereas KRAS G12D inhibitors require non-covalent approaches because G12D lacks a reactive cysteine residue. Pan-RAS inhibition describes the breadth of RAS allele or isoform coverage, while RAS(ON) inhibition describes state-selective targeting of active GTP-bound RAS. These concepts can overlap; multi-selective RAS(ON) inhibitors such as daraxonrasib/RMC-6236 broadly target active-state RAS proteins. Targeted degraders recruit E3 ubiquitin ligases to induce KRAS ubiquitination and proteasomal degradation.
Figure 1 Mechanistic classes of KRAS-targeted therapies. The Upper panels compare key mechanistic features and illustrate the canonical KRAS GDP/GTP activation cycle. The Lower Panels: KRAS-targeted strategies have evolved from allele-specific KRAS G12C inhibition to KRAS G12D inhibition, multi-selective RAS targeting/RAS(ON) active-state inhibition, and targeted protein degradation. KRAS G12C inhibitors covalently bind the switch-II pocket of GDP-bound KRAS G12C and trap KRAS in an inactive OFF state, whereas KRAS G12D inhibitors require non-covalent approaches because G12D lacks a reactive cysteine residue. Pan-RAS inhibition describes the breadth of RAS allele or isoform coverage, while RAS(ON) inhibition describes state-selective targeting of active GTP-bound RAS. These concepts can overlap; multi-selective RAS(ON) inhibitors such as daraxonrasib/RMC-6236 broadly target active-state RAS proteins. Targeted degraders recruit E3 ubiquitin ligases to induce KRAS ubiquitination and proteasomal degradation.CC BY · PubMed Central
Figure 2 Mechanisms of resistance and adaptive signaling in KRAS-targeted therapy. KRAS-targeted therapy can be limited by on-target resistance, adaptive pathway reactivation, tumor microenvironment-mediated resistance, and non-genetic lineage plasticity. On-target mechanisms include secondary KRAS mutations, KRAS amplification, and activation of alternative RAS isoforms, which maintain MAPK signaling despite KRAS inhibition. Off-target mechanisms include feedback activation of receptor tyrosine kinases such as EGFR, HER2, FGFR, and MET, as well as SHP2-SOS1-mediated upstream RAS reactivation. Tumor microenvironmental factors, including CAF-derived growth factors, cytokines, extracellular matrix remodeling, and immune-suppressive signaling, may further promote resistance. Lineage plasticity and histologic transformation can reduce KRAS–MAPK dependency and allow tumor persistence. These mechanisms underlie primary and acquired resistance and support the rationale for biomarker-guided combination strategies.
Figure 2 Mechanisms of resistance and adaptive signaling in KRAS-targeted therapy. KRAS-targeted therapy can be limited by on-target resistance, adaptive pathway reactivation, tumor microenvironment-mediated resistance, and non-genetic lineage plasticity. On-target mechanisms include secondary KRAS mutations, KRAS amplification, and activation of alternative RAS isoforms, which maintain MAPK signaling despite KRAS inhibition. Off-target mechanisms include feedback activation of receptor tyrosine kinases such as EGFR, HER2, FGFR, and MET, as well as SHP2-SOS1-mediated upstream RAS reactivation. Tumor microenvironmental factors, including CAF-derived growth factors, cytokines, extracellular matrix remodeling, and immune-suppressive signaling, may further promote resistance. Lineage plasticity and histologic transformation can reduce KRAS–MAPK dependency and allow tumor persistence. These mechanisms underlie primary and acquired resistance and support the rationale for biomarker-guided combination strategies.CC BY · PubMed Central
Figure 3 Biomarker-guided framework for KRAS-targeted therapy in advanced and perioperative settings. In advanced disease, tumor lineage and clinical context guide KRAS status assessment using tissue and/or liquid biopsy, followed by therapeutic selection according to KRAS allele, tumor type, and available treatment options. Serial liquid biopsy and ctDNA monitoring may support molecular response assessment and detection of emerging resistance mechanisms, which may inform subsequent resistance-directed therapy or clinical trial selection. In the perioperative setting, postoperative ctDNA-based MRD assessment may identify patients at increased recurrence risk; however, MRD-guided escalation, KRAS-directed adjuvant treatment, and perioperative ctDNA-guided adaptation remain investigational and require prospective validation. ctDNA and tissue biopsy are complementary, with ctDNA enabling serial molecular monitoring and tissue biopsy providing histologic and microenvironmental information.
Figure 3 Biomarker-guided framework for KRAS-targeted therapy in advanced and perioperative settings. In advanced disease, tumor lineage and clinical context guide KRAS status assessment using tissue and/or liquid biopsy, followed by therapeutic selection according to KRAS allele, tumor type, and available treatment options. Serial liquid biopsy and ctDNA monitoring may support molecular response assessment and detection of emerging resistance mechanisms, which may inform subsequent resistance-directed therapy or clinical trial selection. In the perioperative setting, postoperative ctDNA-based MRD assessment may identify patients at increased recurrence risk; however, MRD-guided escalation, KRAS-directed adjuvant treatment, and perioperative ctDNA-guided adaptation remain investigational and require prospective validation. ctDNA and tissue biopsy are complementary, with ctDNA enabling serial molecular monitoring and tissue biopsy providing histologic and microenvironmental information.CC BY · PubMed Central

Verification

Claims the paper makes

40 Valid · 8 Not valid · 8 Not checked · 48 Own results and interpretations

55 more claims · 24 with their cited sources checked

Create a free account to see all 104 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 36
  • Probably not a substantial claim. 9

Create a free account to see these claims.

Citations

Cites

Show all 81 references

Metadata

Authors
Kano, Y.
Affiliations
Institute of Science Tokyo (JP)
Corresponding author
Kano, Yoshihito
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2026-06-26
Volume
27
Issue
13
Pages
5796
ISSN
1422-0067 (ISSN-L)
OpenAlex
W7166532892
Cited by
0
References
81
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
KRAS, KRAS G12C inhibitors, KRAS G12D inhibitors, pan-RAS inhibitors, sotorasib, adagrasib, resistance mechanisms, tumor heterogeneity, circulating tumor DNA, minimal residual disease, precision oncology, KRAS-mutant cancer
MeSH terms
Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Precision Medicine, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies. https://app.cochat.ai/papers/10.3390/ijms27135796
The paper
Kano, Y. (2026). Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27135796

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.